Literature DB >> 31987984

Current trends in theranostics for rheumatoid arthritis.

Yamini Madav1, Kalyani Barve2, Bala Prabhakar3.   

Abstract

The very complexity of Rheumatoid Arthritis (RA) makes its prognosis and management challenging. The manifestations pertaining to RA emerge in the late stage of the disease when the damage to bone and cartilage has already occurred. Therefore early diagnosis of RA becomes critical in order to avoid further complications and disabilities. In such a scenario, theranostics can be an ideal solution to tackle the barriers to disease management in RA patients. Nanotechnology has paved the way for emerging theranostics to achieve better targetability and high performance. The shortcomings of current diagnostic techniques and pharmacological treatment are addressed in this review. The article also summarizes the laboratory studies that have reported promising theranostic entities for RA diagnosis, treatment and discusses the outcomes of each. Novel platforms combined with newer techniques have found application in the theranostics of RA. These platforms include gold nanorods, nanoshells, nanowhiskers, magnetic nanoparticles, solid and mesoporous silica nanoparticles, etc. Photodynamic, chemo-photo responsive, magnetic field based imaging and simultaneous stimulation have been reported for the release of therapeutic moieties from these nanoplatform. Theranostics can also assist clinicians in determining the respondents and non-respondents to biological response modifiers and other treatments available for RA. This not only plays an important role in selecting the suitable therapy for every patient but also in monitoring the progress of treatment in the patient. The advantages of theranostics over current diagnosis and treatment for RA are tremendous. Hence it holds great opportunities for progress and enhancement of RA disease management.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diagnosis; Imaging; Nanotechnology; Photodynamic therapy

Year:  2020        PMID: 31987984     DOI: 10.1016/j.ejps.2020.105240

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  8 in total

Review 1.  Precision medicine: the precision gap in rheumatic disease.

Authors:  Chung M A Lin; Faye A H Cooles; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2022-10-10       Impact factor: 32.286

2.  Total Saponins of Radix Clematis Regulate Fibroblast-Like Synoviocyte Proliferation in Rheumatoid Arthritis via the LncRNA OIP5-AS1/MiR-410-3p/Wnt7b Signaling Pathway.

Authors:  Lingyu Pan; Yuan Sun; Hui Jiang; Yan Chen; Yeke Jiang; Yanquan Han; Yongzhong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-27       Impact factor: 2.650

3.  lncRNA expression profiles related to apoptosis and autophagy in peripheral blood mononuclear cells of patients with rheumatoid arthritis.

Authors:  Jianting Wen; Jian Liu; Hui Jiang; Lei Wan; Ling Xin; Yue Sun; Pingheng Zhang; Yanqiu Sun; Ying Zhang; Xinlei Du; Xin Wang; Jie Wang
Journal:  FEBS Open Bio       Date:  2020-07-22       Impact factor: 2.693

Review 4.  Marine-Derived Biologically Active Compounds for the Potential Treatment of Rheumatoid Arthritis.

Authors:  Muhammad Bilal; Maimoona Qindeel; Leonardo Vieira Nunes; Marco Thúlio Saviatto Duarte; Luiz Fernando Romanholo Ferreira; Renato Nery Soriano; Hafiz M N Iqbal
Journal:  Mar Drugs       Date:  2020-12-29       Impact factor: 5.118

5.  lncRNAS56464.1 as a ceRNA promotes the proliferation of fibroblast‑like synoviocytes in experimental arthritis via the Wnt signaling pathway and sponges miR‑152‑3p.

Authors:  Hui Jiang; Jian Liu; Chang Fan; Jing Wang; Weiping Li
Journal:  Int J Mol Med       Date:  2021-01-15       Impact factor: 4.101

6.  Network Pharmacology and Molecular Docking Study of the Chinese Miao Medicine Sidaxue in the Treatment of Rheumatoid Arthritis.

Authors:  Ning Wu; Taohua Yuan; ZhiXin Yin; Xiaotian Yuan; Jianfei Sun; Zunqiu Wu; Qilong Zhang; Carl Redshaw; Shenggang Yang; Xiaotian Dai
Journal:  Drug Des Devel Ther       Date:  2022-02-19       Impact factor: 4.162

7.  The protein corona modulates the inflammation inhibition by cationic nanoparticles via cell-free DNA scavenging.

Authors:  Xingliang Liu; Huiyi Liang; Yanzi Yan; Jingjiao Wu; Massimo Bottini; Lixin Liu; Yongming Chen
Journal:  Bioact Mater       Date:  2021-11-03

8.  Long Non-Coding RNA PVT1 and Its Target miRNA-146a as Potential Prognostic Biomarkers in Rheumatoid Arthritis Patients.

Authors:  Randa Erfan; Olfat G Shaker; Mahmoud A F Khalil; Yumn A Elsabagh; Azza M Ahmed; Abeer K Abu-El-Azayem; Mohamed S Gomaa; Asmaa Mohammed
Journal:  Life (Basel)       Date:  2021-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.